Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung […]
Amgen (NASDAQ: AMGN) has agreed to take Otezla (apremilast) off of Celgene Corporation‘s (NASDAQ: CELG) hands. The Federal Trade Commission ruled the drug had to be divested due to concerns over competition with Bristol-Myers Squibb‘s (NYSE: BMY) pipeline. Bristol-Myers announced it was buying Celgene last January for $74 billion. In this deal, Amgen gains the worldwide […]
Amgen and CytomX Therapeutics are collaborating on a strategic immuno-oncology program that could be worth up to $1.5 billion for CytomX.